S40 receive this, 2-year relapse-free survival was 73% and 2-year OS was 78%. Prospective trials are now formally evaluating this therapy. There are a wide range of novel molecularly targeted therapies in development for AML, many with activity restricted to molecularly defined subgroups. Investigation of their role in the treatment of MRD relapse is likely to prove extremely fruitful. Although to date a survival benefit for early intervention has only been demonstrated in the NPM1 and FLT3 ITD mutated subset, the benefits for intervention with targeted therapies at MRD relapse extend beyond overall survival, providing patients a chance to be treated for relapse at home, with minimal hospital visits and with oral agents – in stark contrast to the experience of those treated with salvage chemotherapy regimens.
RkJQdWJsaXNoZXIy MTk3NTQxMg==